VIP

Vasoactive Intestinal Peptide (VIP) is a 28-amino-acid neuropeptide utilized off-label for its immunomodulatory, anti-inflammatory, and vasodilatory effects, primarily in the context of chronic inflammation and headache relief. Users typically run doses ranging from 25 µg to 200 µg daily, with 100 µg serving as the community modal dose, while clinician-led protocols utilize 200 µg daily. Readers should note that the off-label evidence base is thinner than the current discourse suggests, as most exploratory indications lack posted trial results, and the registered trial program shows a 19% withdrawal rate. Reports of nausea and sleep disturbances occasionally surface, though injection-site reactions have not been a consistent theme.

Half-life~1 min

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.63.42.83.23.02.0

Research Evidence

Evidence shape

VIP possesses high-tier evidence primarily centered on diagnostic and mechanistic research, supported by a total of 16 registered trials. While the literature includes Phase 3-grade data and two blinded studies with results, the vast majority of the 14 mapped indications remain exploratory or rely on single-trial data. The clinical record shows a 19% withdrawal rate across eight distinct sponsors, and despite the breadth of research into conditions like respiratory failure and COVID-19, most indications lack published results or remain in the long-tail of early-stage investigation.

Depthhow much
16 registered trials
11 completed · 2 with posted results · 1 recruiting / active · combined n=676
Breadthhow many areas
14 indications mapped
2 with results · 10 thin / exploratory · 1 animal-only · 10 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
2 blinded with results · 8 distinct sponsors · 19% withdrawal rate · AE table from NCT04311697 · 17 linked publications on registered trials
Breadth and depth31 rows captured
Human
direct clinical signal
17
Animal
translational support
12
In vitro
mechanistic support
2
HighMediumLow

Anecdotal efficacy

VIP side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Peptide Pros
--
5 mg
$7.50
$1.5/mg
2
BulkGLP
USA
1000 mg
$2,263.00
$2.26/mg
3
peptidesourcehub.com
--
100 mg
$234.90
$2.35/mg
4
Peppyandme
US
10 mg
$30.00
$3/mg
5
Bulk Peptide Supply
unknown
10 mg
$36.00
$3.6/mg
6
Raccoon Peptides
GB
10 mg
$38.93
$3.89/mg

price offers can be sorted by column

1-6 of 121

VIP dosing & protocol

How VIP is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 11
weight-based
Typical dose
—
0
50 µg
100 µg
150 µg
200 µg
across 1 dosed source · darker = more agree
Frequency
daily
Route
IV

In research trials, VIP was given at 1000 mg per square meter of body surface area, administered intravenously each day.

11 sources
Clinician practice
Doctor & published-protocol guidance · n = 1
Typical dose
200 µg
typical
0
50 µg
100 µg
150 µg
200 µg
across 1 dosed source · darker = more agree
By reported cadence
Daily200 µg · n=1
Frequency
daily
Route
IV

The sole source, the Peptide List, reports a dose of 200 mcg of VIP delivered intravenously once per day for clinicians.

1 source
Anecdotal
Community-reported real-world use · n = 3
Typical dose
100 µg25 µg – 200 µg
typical
0
50 µg
100 µg
150 µg
200 µg
distribution of 4 reported doses · darker = more
Frequency
unspecified
Route
intranasal

Community reports show intranasal VIP doses ranging from 25 µg to 200 µg, with one user noting 100 µg per day; most did not specify frequency or cycling.

3 sources

Related peptides

ThymalinLL-37Thymosin Alpha-1Thymulin